Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about MCK, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|
Also used in these trials (approved or third-party drugs, not MCK's own candidates): Dronedarone.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
MCK holds $6.5B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MCK files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Vanguard Capital Management | Institution (13G, 5%+) | 9,180,981 | 7.95% | 2026-03-31 |
| Britt J. Vitalone EVP & CFO |
Insider | 22,506 | 0.02% | 2026-05-23 |
| Ramesh (NMN) Srinivasan EVP and Chief Strategy Officer · +368 options |
Insider | 11,959 | 0.01% | 2026-08-01 |
| Brian S. Tyler Chief Executive Officer, Director |
Insider | 6,135 | 0.01% | 2026-07-07 |
| LeAnn B Smith EVP & Chief HR Officer |
Insider | 4,798 | 0.00% | 2026-06-01 |
| Francisco Fraga EVP, CIO and CTO |
Insider | 4,415 | 0.00% | 2026-11-05 |
| Michele Lau EVP and Chief Legal Officer · +725 options |
Insider | 3,386 | 0.00% | 2026-05-26 |
| Thomas L Rodgers EVP, Chief Strategy & BDO |
Insider | 2,268 | 0.00% | 2026-06-01 |
| Dominic J Caruso Director |
Insider | 927 | 0.00% | 2026-07-22 |
| Kathleen Wilson-Thompson Director |
Insider | 578 | 0.00% | 2026-07-22 |
| Maria Martinez Director |
Insider | 578 | 0.00% | 2026-07-22 |
| Napoleon B JR Rutledge SVP, Controller & CAO |
Insider | 521 | 0.00% | 2026-09-08 |
Share count 115,456,664 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MCK and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →